Technical Analysis for PASG - Passage Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Historical PASG trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| Bearish Engulfing | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| 200 DMA Resistance | Bearish | -2.66% | |
| 20 DMA Resistance | Bearish | -2.66% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.66% | |
| Earnings Movers | Other | -2.66% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Down 5% | about 6 hours ago | |
| Fell Below 10 DMA | about 6 hours ago | |
| 10 DMA Support | about 6 hours ago | |
| Down 3% | about 6 hours ago | |
| 60 Minute Opening Range Breakdown | about 8 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/03/2021
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Rare Diseases Nervous System Disorders Central Nervous System Disorders Lipid Storage Disorders Monogenic Gm1 Medicine Products Rare Tadataka Yamada
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Rare Diseases Nervous System Disorders Central Nervous System Disorders Lipid Storage Disorders Monogenic Gm1 Medicine Products Rare Tadataka Yamada
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 38.23 |
| 52 Week Low | 8.09 |
| Average Volume | 452,256 |
| 200-Day Moving Average | 20.61 |
| 50-Day Moving Average | 23.02 |
| 20-Day Moving Average | 20.17 |
| 10-Day Moving Average | 19.11 |
| Average True Range | 1.75 |
| ADX | 14.43 |
| +DI | 24.62 |
| -DI | 18.79 |
| Chandelier Exit (Long, 3 ATRs ) | 18.01 |
| Chandelier Exit (Short, 3 ATRs ) | 22.18 |
| Upper Bollinger Band | 22.83 |
| Lower Bollinger Band | 17.51 |
| Percent B (%b) | 0.36 |
| BandWidth | 26.38 |
| MACD Line | -0.94 |
| MACD Signal Line | -1.06 |
| MACD Histogram | 0.1224 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 24.08 | ||||
| Resistance 3 (R3) | 24.39 | 23.14 | 23.31 | ||
| Resistance 2 (R2) | 23.14 | 21.96 | 22.99 | 23.05 | |
| Resistance 1 (R1) | 21.29 | 21.23 | 20.67 | 20.98 | 22.79 |
| Pivot Point | 20.04 | 20.04 | 19.73 | 19.89 | 20.04 |
| Support 1 (S1) | 18.19 | 18.86 | 17.57 | 17.88 | 16.07 |
| Support 2 (S2) | 16.94 | 18.13 | 16.79 | 15.81 | |
| Support 3 (S3) | 15.09 | 16.94 | 15.56 | ||
| Support 4 (S4) | 14.78 |
